Ampio Pharmaceuticals (NYSE:AMPE) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Ampio Pharmaceuticals (NYSE:AMPE) in a report published on Thursday. The firm issued a sell rating on the stock.

Ampio Pharmaceuticals Trading Up 3,211.5 %

Shares of Ampio Pharmaceuticals stock opened at $0.09 on Thursday. Ampio Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $2.91. The firm has a market capitalization of $97,723.50, a P/E ratio of -0.01 and a beta of 3.71. The business has a fifty day simple moving average of $0.01 and a two-hundred day simple moving average of $0.02.

Ampio Pharmaceuticals Company Profile

Ampio Pharmaceuticals, Inc, a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.